Elevation Oncology, Inc. ELEV
Institutional shares held
32 Million
50K
calls
0
puts
Total value of holdings
$11.5M
$18K
calls
$0
puts
Market Cap
$8.39M
23,300,900
Shares Out.
Institutional ownership
137.35%
# of Institutions
66
We take great care to ensure that the data presented and summarized in this overview for Elevation Oncology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELEV
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$2.16 Million0.12% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.89MShares$2.12 Million1.64% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.02 Million0.29% of portfolio
-
Black Rock Inc. New York, NY2.49MShares$896,4890.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.26MShares$812,4080.0% of portfolio
-
Opaleye Management Inc. Boston, MA1.44MShares$519,1410.13% of portfolio
-
Deltec Asset Management LLC1.44MShares$517,0900.1% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.42MShares$512,8000.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.01MShares$363,7100.0% of portfolio
-
Rangeley Capital, LLC New Canaan, CT905KShares$325,9040.4% of portfolio
Latest Institutional Activity in ELEV
Top Purchases
Top Sells
About ELEV
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Insider Transactions at ELEV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 23
2025
|
Timothy P Clackson |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
47,330
-100.0%
|
$0
$0.36 P/Share
|
|
Jul 23
2025
|
Tammy Furlong CHIEF FINANCIAL OFFICER |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
37,957
-100.0%
|
$0
$0.36 P/Share
|
|
Jun 16
2025
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,627
-3.09%
|
$0
$0.39 P/Share
|
|
Jun 16
2025
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,560
+7.74%
|
-
|
|
May 15
2025
|
Tammy Furlong CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
784
-7.22%
|
$0
$0.3 P/Share
|
|
May 15
2025
|
Tammy Furlong CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,643
+19.57%
|
-
|
|
May 15
2025
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,303
-1.65%
|
$0
$0.3 P/Share
|
|
May 15
2025
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+4.29%
|
-
|
|
Mar 16
2025
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,628
-3.36%
|
$0
$0.53 P/Share
|
|
Mar 16
2025
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,562
+8.35%
|
-
|
|
Feb 15
2025
|
Valerie Malyvanh Jansen CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,189
-29.65%
|
$0
$0.67 P/Share
|
|
Feb 15
2025
|
Valerie Malyvanh Jansen CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+50.0%
|
-
|
|
Feb 15
2025
|
Tammy Furlong CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,869
-13.42%
|
$0
$0.67 P/Share
|
|
Feb 15
2025
|
Tammy Furlong CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,675
+24.99%
|
-
|
|
Feb 15
2025
|
David Dornan CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,152
-44.29%
|
$0
$0.67 P/Share
|
|
Feb 15
2025
|
David Dornan CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+50.0%
|
-
|
|
Feb 15
2025
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
9,211
-6.85%
|
$0
$0.67 P/Share
|
|
Feb 15
2025
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+15.68%
|
-
|
|
Dec 16
2024
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,629
-4.06%
|
$0
$0.64 P/Share
|
|
Dec 16
2024
|
Joseph J Ferra Jr CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,563
+9.92%
|
-
|
Last 12 Months Summary
Buy / Acquisition
121K
Shares
From
4
Insiders
| Exercise of conversion of derivative security | 121K shares |
|---|
Sell / Disposition
128K
Shares
From
6
Insiders
| Disposition due to a tender of shares in a change of control transaction | 85.3K shares |
|---|---|
| Payment of exercise price or tax liability | 43.1K shares |